Anduril Industries and General Atomics displayed full-scale models of their planned NGAD drones, which will work in tandem ...

The Air Force may have been caught off guard or was just unprepared when President Donald Trump said the next generation ...

Luckily he has a blueprint to work from. The AFL and Sheedy wrote it for him. Michael Chammas and Andrew “Joey” Johns dissect the upcoming NRL round, plus the latest footy news, results and ...

Rahul Gandhi’s latest article is a blueprint for manufacturing fake narratives, owing to his sadness and desperation of losing election after election.

The Progressive National Party (PNP) recently commemorated its first 100 days in office, marking the milestone with community engagement events and a review of key initiatives undertaken since its ...

In this article, we are going to take a look at where Blueprint Medicines Corporation (NASDAQ:BPMC) stands against other top-performing stocks on Monday. Blueprint Medicines soared by 26.09 ...

Shares of steel companies soar after President Donald Trump says he will raise tariffs on imported steel to 50% from 25%.

Just five weeks later, Sanofi has made a deal few would describe as “bolt-on,” as it has bought out Massachusetts-based Blueprint Medicines for up to $9.5 billion. With the deal, Sanofi gains ...

Also Read: Blood Cancer-Focused Blueprint Medicines Could Be ‘Attractive Target For Partnerships’: Analyst Sanofi will pay $129.00 per share in cash, representing an equity value of ...

Shares of Blueprint Medicines Corporation BPMC rose sharply in today's pre-market trading. Sanofi SA SNY announced plans to acquire Blueprint Medicines for $9.5 billion. Blueprint Medicines shares ...

PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic ...

PARIS (Reuters) -France's Sanofi (SAN.PA) has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in rare immunology diseases, in the biggest deal ...